Astrazeneca PLC Fundamentals Datasheet and Stock Analysis

Profile

Astrazeneca PLC Company Logo
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

  • Current Price:
     7,167.00p
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
     GB0009895292
  • Market Sector:
     MAIN
  • Main Indices:
     techMARK, FTSE 100, FTSE Eurotop 300, FTSE-350, FTSE All-Share, FTSE All-Share
  • Country of register:
     Great Britain
  • Currency:
     N/A
  • Shares in Issue:
     1,313m
  • Market Cap:
     £95,659m
  • Date Listed:
     13/01/2006
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)

Loading...

Activity Data Not Available

Company Information

CEO and Executive director: Pascal Soriot  CFO & Executive Director: Marc Dunoyer  Non-Executive Chairman: Leif Johansson  Senior Independent Non-Executive Director: John Varley  Non-Executive Dir: Rudy Markham, Marcus Wallenberg, Graham Chipchase, Bruce Burlington, Ann Cairns, Genevieve Berger, Shriti Vadera, Jean-Philippe Courtois Prof Dame Nancy Rothwell  

  • Registrars:
     Equiniti
  • Address:
     2 Kingdom Street, London, W2 6BD
  • Phone:
     +44 (0)20 7604 8000
  • Website:
     http://www.astrazeneca.com
Analysis
Composite Ranking: 78
Historic EPS Ranking: 53
Forecast EPS Ranking: 
Price Relative Strength: 3
Industry Strength: C
SMR Ranking: A
ROCE Ranking: B
Accumulation/Dist: B
Mkt Accumulation/Dist: E
Unbroken Annual EPS: D
Unbroken Interim EPS: C
PEG Current Ranking: B
PEG Forecast Ranking: A
PE Current Ranking: H
PE Forecast Ranking: D
Margin Current Ranking: B
Margin Forecast Ranking: B
Chart
Add Indicator




loading




Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Fundamentals
201320142015201620172018201920202021E
Day/Month31/1231/1231/1231/1231/1231/1231/1231/1231/12
Revenue$m25,711.0026,095.0024,708.0023,002.0022,465.0022,090.0024,384.0026,617.00$m22,375.75
Operating Profit/(loss)$m3,712.002,137.004,114.004,902.003,677.003,387.002,924.005,162.00$m0.00
Profit Before Tax$m3,267.001,246.003,069.003,552.002,227.001,993.001,548.003,916.00$m6,382.07
Profit After Tax$m2,571.001,235.002,826.003,406.002,868.002,050.001,227.003,144.00$m0.00
Profit After Tax (from discontinued operations)$m0.000.000.000.000.000.000.000.00$m0.00
Overall Profit for the Period$m2,571.001,235.002,826.003,406.002,868.002,050.001,227.003,144.00$m0.00
EPS Growth%(58.79)(51.96)127.5523.77(14.13)(28.27)(39.41)136.89%23.00
Earnings Per Share¢204.0098.00223.00276.00237.00170.00103.00244.00p384.07
Op. Cash Flow P/S¢5.905.582.633.272.822.072.283.66$0.00
Cash Flow P/S Grth%1,304.76(5.42)(52.87)24.33(13.76)(26.60)10.1460.53%0.00
Net Cash Flow P/S¢736.18503.96493.67396.680.00381.29412.680.00$0.00
Capital Exp P/S$0.000.000.000.000.000.000.000.00$0.00
Tax Rate%21.300.887.964.150.00(2.71)19.290.00%0.00
P/E Ratiox22.7026.6028.6022.0029.7047.30102.1041.70x19.30
P/E Growth$0.000.000.000.000.000.000.000.30$0.80
Turnover Per Share$2,053.592,067.751,954.751,818.340.001,743.491,874.250.00$0.00
Pre-Tax Profit / Share$260.9498.73242.80280.790.00157.30118.990.00$0.00
Operating Margin%14.448.1916.6521.3116.3715.3311.9919.39%0.00
ROCE%9.434.269.0910.417.647.576.8211.18%0.00
ROE%10.895.7614.8220.9920.1315.7110.4322.23%0.00
Mkt Cap$m45,258.1257,378.2858,351.9056,144.5567,225.3274,172.49100,431.0497,155.75$m0.00
Dividend Per Share¢280.00280.00280.00280.00280.00280.00280.00280.00p210.86
DPS Growth%0.000.000.000.000.000.000.000.00%0.00
Dividend Yield%6.004.704.404.604.003.502.702.80%2.90
Dividend Coverx1.801.531.521.541.530.610.370.87x0.00
Shareholder Funds$m23,224.0019,627.0018,490.0014,854.0014,960.0012,468.0013,127.0015,622.00$m0.00
Net Borrowings$m11,591.0044,831.0088,131.00117,901.00(33,241.00)142,821.00128,581.00(78,321.00)$m0.00
Net Assets$m23,253.0019,646.0018,509.0016,669.0016,642.0014,044.0014,596.0015,638.00$m0.00
Net Assets P/S$(221.65)(1,021.00)(1,260.84)(1,784.58)0.00(1,548.70)(1,376.25)0.00$0.00
Financials
Latest Forecast
Div Yield2.8%2.8%
Div Cover0.9%1.8%
Op Margin19.4%26.8%
ROCE76.3%
Director Deals
Traded Action Notifier Price Amount Value
16-Dec-20BuyPhilip A J Broadley7,625.00p1,310,399,887.50
16-Dec-20BuyMichel Demare7,680.00p1,300,399,840
16-Dec-20BuyNazneen Rahman7,677.60p259,319,884.98
16-Dec-20BuyNazneen Rahman7,679.10p258,319,812.08
16-Dec-20BuyEuan Ashley103.04$350$29,738.60
18-Mar-20BuyTony Mok76.64$500$31,598.91
18-Mar-20BuyTony Mok76.64$500$29,937.52
26-Feb-20BuyTony Mok96.00$500$39,581.10
26-Feb-20BuyTony Mok96.00$500$37,500.03
17-Feb-20BuyMichel Demare7,313.00p700,351,191
First PagePrev PageNext Page  Rows per page
Shareholders
1,313m    Major: 24%    Director: 0%
Notifier Holding Value
Pascal Soriot609,188,,013,833
Marc Dunoyer439,130,727,142.50
Marcus Wallenberg63,646,598,423.50
Leif Johansson39,009,818,400.25
Graham Chipchase3,000Ø,750
  Rows per page
Gearing & Cover
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
12-Apr-21Shore CapitalBuy7225.00p0.00p0.00pReiteration
08-Apr-21DeutscheBuy7287.00p0.00p10200.00pReiteration
08-Apr-21CitigroupBuy7287.00p0.00p10000.00pReiteration
14-Jan-21Berenberg BankBuy7662.00p105.00p100.00pReiteration
14-Jan-21BarclaysOverweight7559.00p0.00p0.00pReiteration
17-Dec-20Liberum CapitalBuy7542.00p9770.00p9430.00pReiteration
23-Nov-20Morgan StanleyEqual-weight8000.00p9000.00p9400.00pReiteration
17-Nov-20JefferiesBuy8180.00p0.00p8100.00pReiteration
03-Nov-20JP Morgan CazenoveOverweight7963.00p0.00p9500.00pReiteration
08-Jun-20Credit SuisseOutperform8244.00p9000.00p9000.00pReiteration
First PagePrev PageNext Page  Rows per page
Notes

This functionality requires you to login

Click here to login
Or register for a new account